Zhang Cheng, Li Pan-Pan, Wang Lian-Xin, Xie Yan-Ming, Li Lin
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China Shandong University of Traditional Chinese Medicine Ji'nan 250355, China.
Zhongguo Zhong Yao Za Zhi. 2020 Aug;45(15):3533-3538. doi: 10.19540/j.cnki.cjcmm.20200507.502.
To explore the general characteristics of adverse drug reactions/adverse events(ADR/AE) in patients after using Shujin Jianyao Pills, and explore risk warning signals, this study analyzed 166 cases of ADR/AE reports of Shujin Jianyao Pills collected from 2005 to 2017 based on the National Center for ADR Monitoring spontaneous reporting system(SRS). And the descriptive statistical method was used to analyze general characteristics. The results showed that among the 166 ADR/AE cases, 106 cases were female patients, accounting for 63.86%. Middle-aged and elderly people aged 45 to 64 accounted for the largest proportion(82 cases, 49.40%), which were followed by elderly aged 65 and over(48 cases, 28.91%). ADR/AE involved a wide range of systems and organs, of which skin and its accessories were the most damaged(30 cases, 12.93%), which were followed by systemic damage(27 cases, 11.64%). The top 10 ADR/AE manifestations were rash(15 cases, 6.33%), nausea(14 cases, 5.91%), dizziness(14 cases, 5.91%), abdominal pain(12 cases, 5.06%), pruritus(11 cases, 4.64%), low back pain(11 cases, 4.64%), vomiting(10 cases, 4.22%), hepatocyte damage(9 cases, 3.80%), headache(9 cases, 3.80%), and diarrhea(7 cases, 2.95%). Bayesian confidence propagation neural network(BCPNN) was used to mine the ADR/AE risk early warning signal of Shujin Jianyao Pills, and the propensity score method was used to control the balance of confounding factors. The results suggested warning signs for nausea, diarrhea, rash, and dizziness, vomiting, abdominal pain, headache, liver cell damage. This study provides a basis for the post-marke-ting safety evaluation of Shujin Jianyao Pills, and can provide guidance for its rational clinical use and risk management.
为探讨舒筋健腰丸使用者药品不良反应/不良事件(ADR/AE)的一般特征,探寻风险预警信号,本研究基于国家药品不良反应监测中心自发报告系统(SRS),分析了2005年至2017年收集的166例舒筋健腰丸ADR/AE报告。并采用描述性统计方法分析一般特征。结果显示,166例ADR/AE病例中,女性患者106例,占63.86%。45至64岁的中老年人占比最大(82例,49.40%),其次是65岁及以上老年人(48例,28.91%)。ADR/AE累及系统和器官范围广泛,其中皮肤及其附件损害最为严重(30例,12.93%),其次是全身性损害(27例,11.64%)。ADR/AE前10位表现为皮疹(15例,6.33%)、恶心(14例,5.91%)、头晕(14例,5.91%)、腹痛(12例,5.06%)、瘙痒(11例,4.64%)、腰痛(11例,4.64%)、呕吐(10例,4.22%)、肝细胞损害(9例, 3.80%)、头痛(9例,3.80%)、腹泻(7例,2.95%)。采用贝叶斯置信传播神经网络(BCPNN)挖掘舒筋健腰丸ADR/AE风险预警信号,并采用倾向得分法控制混杂因素的平衡。结果提示恶心、腹泻、皮疹、头晕、呕吐、腹痛、头痛、肝细胞损害等预警信号。本研究为舒筋健腰丸上市后安全性评价提供依据,可为其临床合理使用及风险管理提供指导。